XBiotech Inc.
For the period ended Dec 31, 2025. Filed Mar 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 13, 2026
XBIT$1.91+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders’ Equity
(in thousands, except number of shares)
| Number of Shares | Common Stock Amount | Accumulated Deficit | Total | |
|---|---|---|---|---|
| Balance at December 31, 2023 | 30,436,964 | $271,152 | $(52,306) | $218,846 |
| Net loss | - | - | (38,531) | (38,531) |
| Issuance of common stock under stock option plan | 50,767 | 200 | - | 200 |
| Share-based compensation expense | - | 1,753 | - | 1,753 |
| Balance at December 31, 2024 | 30,487,731 | $273,105 | $(90,837) | $182,268 |
| Net loss | - | - | (45,540) | (45,540) |
| Share-based compensation expense | - | 3,622 | - | 3,622 |
| Balance at December 31, 2025 | 30,487,731 | $276,727 | $(136,377) | $140,350 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.